Zoetis Inc (NYSE:ZTS)
| 206.24 Delayed Data As of Jan 14 |  -0.76 / -0.37%Today’s Change | 141.41 Today|||52-Week Range 249.27 | -15.49% Year-to-Date |
ZTS Regular Dividend: ZTS will begin trading ex-dividend on 01/19/22 with a $0.325 dividend payable to shareholders of record as of 01/20/22.
Latest ZTS News | Press Releases
| First Citizens Financial Corp Buys PGIM Ultra Short Bond ETF, BTC BlackRock Short Maturity Bond ... Jan 13 / GuruFocus News - Paid Partner Content | Why Holding Anthem (ANTM) in Your Portfolio is a Prudent Move? Jan 11 / Zacks.com - Paid Partner Content |
| Why Zoetis Stock Gained 47% in 2021 Jan 12 / MotleyFool.com - Paid Partner Content | Here's Why Zoetis (ZTS) is Poised for a Turnaround After Losing 8.8% in 4 Weeks Jan 10 / Zacks.com - Paid Partner Content |
| Here's Why Seasoned Investors are Retaining Mednax (MD) Jan 12 / Zacks.com - Paid Partner Content | CORT vs. ZTS: Which Stock Is the Better Value Option? Jan 05 / Zacks.com - Paid Partner Content |
| Town & Country Bank & Trust CO dba First Bankers T Buys Danaher Corp, iShares Core 1-5 ... Jan 12 / GuruFocus News - Paid Partner Content | JAZZ's Xywav Gets Orphan Drug Exclusivity for Hypersomnia Jan 04 / Zacks.com - Paid Partner Content |
| Buy the Dip in These 3 Growth Stocks That Just Went on Sale Jan 12 / StockNews.com - Paid Partner Content |
Today’s Trading
| Previous close | 207.00 |
| Today’s open | 206.71 |
| Day’s range | 203.45 - 207.36 |
| Volume | 2,209,116 |
| Average volume (3 months) | 1,628,956 |
| Market cap | $97.5B |
Data as of 4:00pm ET, 01/14/2022
Growth & Valuation
| Earnings growth (last year) | +9.80% |
| Earnings growth (this year) | +21.01% |
| Earnings growth (next 5 years) | +15.27% |
| Revenue growth (last year) | +6.63% |
| P/E ratio | 49.7 |
| Price/Sales | 11.87 |
| Price/Book | 26.00 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| GSKGlaxoSmithKline | +0.41 | +0.91% |
| ---- | ||
| REGNRegeneron Pharmaceut... | -0.87 | -0.14% |
| SNYSanofi | +1.21 | +2.39% |
Data as of 4:00pm ET, 01/14/2022
Financials
| Next reporting date | February 15, 2022 |
| EPS forecast (this quarter) | $0.97 |
| Annual revenue (last year) | $6.7B |
| Annual profit (last year) | $1.6B |
| Net profit margin | 24.54% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Generic |
No executives to display |
Corporate headquarters Parsippany, New Jersey |
Forecasts
